A retro-evolutionary approach to development of peptide-based therapeutics

Michael E. Selsted, MD, PhD
Professor and Chair
Department of Pathology & Laboratory Medicine
Keck School of Medicine
University of Southern California

Thursday, March 26, 2015
Noon to 1 p.m.
UC Irvine Medical Center
101 The City Dr., Building 53, Auditorium
Orange, CA 92868

Global Objectives:
- Review recent advances in the recognition and diagnosis of current and emerging disease states.
- Discuss the pathophysiology of various disease states and the multidisciplinary considerations that affect patient care outcomes.
- Identify recent changes in requirements for accreditation, licensing, and regulatory compliance in across all divisions of pathology.
- Discuss recent developments in scientific research and their application to the practice of pathology and laboratory medicine.
- Discuss recent developments in diagnostic technologies and their application to the provision of enhanced laboratory services.

Statement of Purpose: Scientific and Clinical Advances is a lecture series established to provide continuing updates on the various disciplines of pathology with emphasis placed on the clinical applications of current research and the role of the laboratory in specific areas of patient care. Also addressed are current faculty research updates, technological developments and new diagnostic testing methodologies.

Target Audience: The target audience includes faculty and physicians at UC Irvine Health, community pathologists, and professional and technical staff at UC Irvine Health Pathology Laboratories.

Accreditation Statement: The University of California, Irvine School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement: The University of California, Irvine School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

California Continuing Education Credit: Approved for CA Continuing Education units by the UC Irvine Department of Pathology (#0073) for 1.0 contact hour.

ADA: In compliance with the Americans with Disabilities Act, we will make every reasonable effort to accommodate your request. For any special requests, please contact Laura Ogata at 714.456.6305, at least five days before the meeting.

This activity is in compliance with California Assembly Bill 1195, which requires continuing medical education activities with patient care components to include curriculum in the subjects of cultural and linguistic competency. For specific information regarding Bill 1195 and definitions of cultural and linguistic competency, please visit the CME web site at www.cme.uci.edu.

Disclosure: Michael E. Selsted, MD, PhD, has disclosed that he is the Co-Founder and holder of IP rights for Oryn Therapeutics, LLC, which could be perceived as a potential conflict of interest in his presentation. Dr. Selsted has disclosed that, based on his potential conflict of interest, his presentation has been peer-reviewed for clinical validation, balance and bias. Dr. Selsted further discloses that he will support his presentation with the “best available evidence” from the medical literature and refrain from making recommendations regarding products or services.

Course Director/Planners: Sherif Rezk, MD; Edwin Monuki, MD, PhD; Beverly Wang, MD; and Laura Ogata, MA, MT(AASCP), have disclosed that, as course directors and planners, they have no affiliations, arrangements or financial agreements which could be perceived as a potential conflict of interest.